Physician profile
Lance Michael Harrell
NPI 1447407671
$1,346.87
in general payments reported to CMS, 2019-2025
25 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $426 · 2023: $243 · 2024: $125 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270.73 | 2021-2025 | |
| Abbott Laboratories | $184.94 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $155.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Antares Pharma, INC. | $119.00 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $74.54 | 2022-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $74.18 | 2021-2024 | |
| Lilly USA, LLC | $60.75 | 2021-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $59.60 | 2022-2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $34.16 | 2025 | Breztri, Airsupra |
| Mylan Specialty L.P. | $33.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.95 | 2021 | |
| Ascensia Diabetes Care US INC. | $30.70 | 2025 | |
| Edwards Lifesciences Corporation | $23.17 | 2021 | |
| Seqirus USA INC | $19.69 | 2025 | Flucelvax, Fluad |
| Eisai INC. | $18.64 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.32 | 2025 | The Cologuard Plus Collection Kit |
| Scynexis, INC. | $17.97 | 2022 | |
| Exeltis, USA INC. | $17.40 | 2023 | Slynd |
| Sanofi Pasteur INC. | $16.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.45 | 2022 | |
| Glaxosmithkline, LLC. | $15.68 | 2023 | Trelegy Ellipta |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Shield Therapeutics INC | $13.26 | 2024 | |
| Amarin Pharma, INC. | $12.75 | 2021 | |
| Genentech USA, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.